Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens
The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of...
Gespeichert in:
Veröffentlicht in: | Journal of peptide science 2015-10, Vol.21 (10), p.770-778 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 778 |
---|---|
container_issue | 10 |
container_start_page | 770 |
container_title | Journal of peptide science |
container_volume | 21 |
creator | Laverty, Garry McCloskey, Alice P. Gorman, Sean P. Gilmore, Brendan F. |
description | The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes).
Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.
There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance. |
doi_str_mv | 10.1002/psc.2805 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722180655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3803419421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</originalsourceid><addsrcrecordid>eNpdkUtPFUEQhTtGI4gm_gIziRs3A_2gumeWeCNIIEiiRuOm048aaJwX3T1X7r-nb0BMXFUl56tK1TmEvGV0n1HKD-bk9nlD4RnZZbRtayYa9XzbK6i5ZGqHvErphtKigXxJdrgUjDaS7pLxaMyhtmHqQj9UxuWwDnlTTV219DmadD3FXLkwjmYIrujBVzPOOXisPMawNmUAU2WuTBhTrgb0wZm-aOvgsI7Ym4xlxOTr6QrH9Jq86Eyf8M1j3SPfjz99W32uz7-cnK6Ozmt32DKokflOcIRDaKBFVKptjbdCss4xbqlB13ouPTqpGmNlA9xYzyx0qKzgYMUe-fCwd47T7YIp6yEkh31vRpyWpJninDVUAhT0_X_ozbTEsVxXqOJSCwCyUO8eqcWWJ_Ucw2DiRv91sgD1A_An9Lh50hnV24R0SUhvE9KXX1fb-o8PKePdE2_iby2VUKB_XJzoj2ern-IXHOtLcQ-nyZOO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710895556</pqid></control><display><type>article</type><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</creator><creatorcontrib>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</creatorcontrib><description>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes).
Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.
There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</description><identifier>ISSN: 1075-2617</identifier><identifier>EISSN: 1099-1387</identifier><identifier>DOI: 10.1002/psc.2805</identifier><identifier>PMID: 26310860</identifier><identifier>CODEN: JPSIEI</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; antimicrobial ; Biocompatible Materials ; biofilm ; Biofilms - drug effects ; biomaterials ; Cell Line ; Cell Survival - drug effects ; Cinnamates - chemistry ; Escherichia coli ; Hemolysis - drug effects ; Humans ; kill kinetics ; MBEC ; Microbial Sensitivity Tests ; peptide ; Peptides ; Peptides - adverse effects ; Peptides - chemistry ; Peptides - pharmacology ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus epidermidis</subject><ispartof>Journal of peptide science, 2015-10, Vol.21 (10), p.770-778</ispartof><rights>Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.</rights><rights>Copyright © 2015 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpsc.2805$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpsc.2805$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26310860$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laverty, Garry</creatorcontrib><creatorcontrib>McCloskey, Alice P.</creatorcontrib><creatorcontrib>Gorman, Sean P.</creatorcontrib><creatorcontrib>Gilmore, Brendan F.</creatorcontrib><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><title>Journal of peptide science</title><addtitle>J. Pept. Sci</addtitle><description>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes).
Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.
There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</description><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>antimicrobial</subject><subject>Biocompatible Materials</subject><subject>biofilm</subject><subject>Biofilms - drug effects</subject><subject>biomaterials</subject><subject>Cell Line</subject><subject>Cell Survival - drug effects</subject><subject>Cinnamates - chemistry</subject><subject>Escherichia coli</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>kill kinetics</subject><subject>MBEC</subject><subject>Microbial Sensitivity Tests</subject><subject>peptide</subject><subject>Peptides</subject><subject>Peptides - adverse effects</subject><subject>Peptides - chemistry</subject><subject>Peptides - pharmacology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus epidermidis</subject><issn>1075-2617</issn><issn>1099-1387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtPFUEQhTtGI4gm_gIziRs3A_2gumeWeCNIIEiiRuOm048aaJwX3T1X7r-nb0BMXFUl56tK1TmEvGV0n1HKD-bk9nlD4RnZZbRtayYa9XzbK6i5ZGqHvErphtKigXxJdrgUjDaS7pLxaMyhtmHqQj9UxuWwDnlTTV219DmadD3FXLkwjmYIrujBVzPOOXisPMawNmUAU2WuTBhTrgb0wZm-aOvgsI7Ym4xlxOTr6QrH9Jq86Eyf8M1j3SPfjz99W32uz7-cnK6Ozmt32DKokflOcIRDaKBFVKptjbdCss4xbqlB13ouPTqpGmNlA9xYzyx0qKzgYMUe-fCwd47T7YIp6yEkh31vRpyWpJninDVUAhT0_X_ozbTEsVxXqOJSCwCyUO8eqcWWJ_Ucw2DiRv91sgD1A_An9Lh50hnV24R0SUhvE9KXX1fb-o8PKePdE2_iby2VUKB_XJzoj2ern-IXHOtLcQ-nyZOO</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Laverty, Garry</creator><creator>McCloskey, Alice P.</creator><creator>Gorman, Sean P.</creator><creator>Gilmore, Brendan F.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope></search><sort><creationdate>201510</creationdate><title>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</title><author>Laverty, Garry ; McCloskey, Alice P. ; Gorman, Sean P. ; Gilmore, Brendan F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4915-e1df32e545859ee7799adb361fc12b0aec9d26dec678ab6852abd1b5fe7b325b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>antimicrobial</topic><topic>Biocompatible Materials</topic><topic>biofilm</topic><topic>Biofilms - drug effects</topic><topic>biomaterials</topic><topic>Cell Line</topic><topic>Cell Survival - drug effects</topic><topic>Cinnamates - chemistry</topic><topic>Escherichia coli</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>kill kinetics</topic><topic>MBEC</topic><topic>Microbial Sensitivity Tests</topic><topic>peptide</topic><topic>Peptides</topic><topic>Peptides - adverse effects</topic><topic>Peptides - chemistry</topic><topic>Peptides - pharmacology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus epidermidis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laverty, Garry</creatorcontrib><creatorcontrib>McCloskey, Alice P.</creatorcontrib><creatorcontrib>Gorman, Sean P.</creatorcontrib><creatorcontrib>Gilmore, Brendan F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of peptide science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laverty, Garry</au><au>McCloskey, Alice P.</au><au>Gorman, Sean P.</au><au>Gilmore, Brendan F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens</atitle><jtitle>Journal of peptide science</jtitle><addtitle>J. Pept. Sci</addtitle><date>2015-10</date><risdate>2015</risdate><volume>21</volume><issue>10</issue><spage>770</spage><epage>778</epage><pages>770-778</pages><issn>1075-2617</issn><eissn>1099-1387</eissn><coden>JPSIEI</coden><abstract>The threat of antimicrobial resistance has placed increasing emphasis on the development of innovative approaches to eradicate multidrug‐resistant pathogens. Biofilm‐forming microorganisms, for example, Staphylococcus epidermidis and Staphylococcus aureus, are responsible for increased incidence of biomaterial infection, extended hospital stays and patient morbidity and mortality. This paper highlights the potential of ultrashort tetra‐peptide conjugated to hydrophobic cinnamic acid derivatives. These peptidomimetic molecules demonstrate selective and highly potent activity against resistant biofilm forms of Gram‐positive medical device‐related pathogens. 3‐(4‐Hydroxyphenyl)propionic)‐Orn‐Orn‐Trp‐Trp‐NH2 displays particular promise with minimum biofilm eradication concentration (MBEC) values of 125 µg/ml against methicillin sensitive (ATCC 29213) and resistant (ATCC 43300) S. aureus and activity shown against biofilm forms of Escherichia coli (MBEC: 1000 µg/ml). Kill kinetics confirms complete eradication of established 24‐h biofilms at MBEC with 6‐h exposure. Reduced cell cytotoxicity, relative to Gram‐positive pathogens, was proven via tissue culture (HaCaT) and haemolysis assays (equine erythrocytes).
Existing in nature as part of the immune response, antimicrobial peptides display great promise for exploitation by the pharmaceutical industry in order to increase the library of available therapeutic molecules. Ultrashort variants are particularly promising for translation as clinical therapeutics as they are more cost‐effective, easier to synthesise and can be tailored to specific functional requirements based on the primary sequence allowing factors such as spectrum of activity to be varied. Copyright © 2015 European Peptide Society and John Wiley & Sons, Ltd.
There was a rapid eradication of established two biofilms by short cinnamic–peptide hybrids within 6 h at microgram per millilitre concentrations and no significant toxicity was demonstrated. It is potential as future antimicrobial therapies to combat antimicrobial resistance.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26310860</pmid><doi>10.1002/psc.2805</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1075-2617 |
ispartof | Journal of peptide science, 2015-10, Vol.21 (10), p.770-778 |
issn | 1075-2617 1099-1387 |
language | eng |
recordid | cdi_proquest_miscellaneous_1722180655 |
source | MEDLINE; Wiley Online Library All Journals |
subjects | Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology antimicrobial Biocompatible Materials biofilm Biofilms - drug effects biomaterials Cell Line Cell Survival - drug effects Cinnamates - chemistry Escherichia coli Hemolysis - drug effects Humans kill kinetics MBEC Microbial Sensitivity Tests peptide Peptides Peptides - adverse effects Peptides - chemistry Peptides - pharmacology Staphylococcus aureus Staphylococcus aureus - drug effects Staphylococcus epidermidis |
title | Anti-biofilm activity of ultrashort cinnamic acid peptide derivatives against medical device-related pathogens |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T13%3A41%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-biofilm%20activity%20of%20ultrashort%20cinnamic%20acid%20peptide%20derivatives%20against%20medical%20device-related%20pathogens&rft.jtitle=Journal%20of%20peptide%20science&rft.au=Laverty,%20Garry&rft.date=2015-10&rft.volume=21&rft.issue=10&rft.spage=770&rft.epage=778&rft.pages=770-778&rft.issn=1075-2617&rft.eissn=1099-1387&rft.coden=JPSIEI&rft_id=info:doi/10.1002/psc.2805&rft_dat=%3Cproquest_pubme%3E3803419421%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710895556&rft_id=info:pmid/26310860&rfr_iscdi=true |